Kornimate/medical-research-clean huggingface dataset:
influence of local anesthetic administration on the cancer recurrence rate after pancreatic oncologic surgery

Conditions: Pancreatic Cancer

Summary: study aims to compare the influence of intravenous lidocaine and peridural ropivacaine on postoperative long and short term outcome in patients with pancreatic cancer undergoing surgery. as short term endpoints: postoperative complications and resumption of bowel function. long term endpoints include: 1 and 3 year recurrence and mortality.


Eligibility criteria:
inclusion criteria: * diagnosis of pancreatic cancer * american society of anesthesiologists (asa) risk i - iii exclusion criteria: * chronic pain * chronic medication that may interfere with pain: antiepileptics, nsaid, corticoids * contraindications for any of the study medications * significant psychiatric disorders (major depression, bipolar disorders, schizophrenia, etc.) * convulsive disorders requiring medication during the last 2 years * liver cirrhosis/chronic kidney disease stage iv or v/chronic heart failure class iii or iv/ decompensated diabetes * corticoid dependent asthma * autoimmune disorders * anti-arrhythmic medication (verapamil, propafenone, amiodarone) that may interfere with lidocaine's anti-arrhythmic effects * refusal for study participation
an association between asthma severity and capnography parameters

Conditions: Asthma

Summary: asthma is a common chronic disorder of the airways characterized by periods of reversible airflow obstruction known as asthma episodes or attacks. asthma attacks are caused by chronically hyperactive (contraction of the muscles surrounding the airways) and inflamed airways, leading to airflow obstruction, and may be mild, moderate, or severe enough to become life-threatening events. severity of asthma exacerbation is assessed through medical history and lung function measurements with spirometer and requires full cooperation of the patient. thus, in uncooperative populations or during emergency medical situations the spirometer cannot be used. as an alternative, capnography data has been proposed as an indicator of bronchospasm in asthma. previous studies found correlations between the capnography parameters and methacholine challenge in asthma patients. however, the relationship between capnography parameters and severity of asthma or severity of asthma exacerbation have not been well characterized. the study hypothesis is that within the clinical population that is invited to do the methacholine challenge, a different waveform pattern in asthma patients will be detected and possibly a correlation between the severity of obstruction and pattern of waveform during the methacholine challenge. in this proposed feasibility observational study, sixty subjects, both men and women, who will be invited to participate in the methacholine challenge in the institute of pulmonary medicine at rabin medical center, will be recruited to the study. respiratory information will be recorded using the capnostreamtm20p while the subjects will wear the non-invasive smart capnoline® plus sampling line. additionally, feno will be measured using a denox 88 device during the methacholine challenge.


Eligibility criteria:
inclusion criteria: 1. the subject was invited to participate in methacholine challenge for the purposes of clinical assessment, with no relation to this study 2. age 18-70 3. ability to sign informed consent form exclusion criteria: 1. cannot or not willing to have capnography measurement during the entire methacholine challenge 2. has or had in the past chronic obstructive pulmonary disease (copd)
adjuvant chemotherapy following radical cystectomy to treat locally advanced bladder cancer

Conditions: Bladder Cancer

Summary: effect of adjuvant chemotherapy to control tumor progression in patients after cystectomy for locally advanced bladder cancer.

effect of adjuvant chemotherapy based on gemcitabine and cisplatin to control tumor progression in patients after cystectomy for locally advanced bladder cancer.

Eligibility criteria:
inclusion criteria: 1. male or female, 18 years of age or older, estimated life expectancy ≥ 6 months. 2. pathologically confirmed localized invasive bladder cancer following standardize radical cystectomy and pelvic lymphadenectomy. 3. transitional cell carcinoma of bladder, stage pt3n0m0.transitional cell carcinoma may be with or without squamous cell carcinoma and/or adenocarcinoma components. 4. electrocorticography(ecog) performance status 0-2. 5. blood routine:absolute neutrophil count (anc) ≥ 1500/μl,white blood cell count ≥ 3000/μlplatelets ≥ 100,000/μl,hemoglobin ≥ 10.0 g/dl, 6. total serum bilirubin≤ 1.5 x upper limit of normal (uln).serum aspartate transaminase (ast; serum glutamic oxaloacetic transaminase(sgot)) and serum alanine transaminase (alt; serum glutamic pyruvic transaminase (sgpt)) ≤ 2.5 x upper limit of normal (uln). 7. creatinine clearance rate,ccr ≥ 60% 8. ecg：no arrhythmias, no myocardial infarction. * signed and dated informed consent document indicating that the patient (or legally acceptable representative) has been informed of all pertinent aspects of the trial prior to enrollment. * willingness and ability to comply with scheduled visits, treatment plans, laboratory tests,and other study procedures. exclusion criteria: 1. past history of systemic chemotherapy 2. serious heart and lung dysfunction. 3. associated with central or peripheral neuropathy greater than 2 grade. 4. evidence of distant metastasis beyond the pelvis.
evaluating microneedling with cbd and hempseed oil for acne vulgaris safety and efficacy

Conditions: Acne Vulgaris (Disorder)

Summary: this is a prospective, single center, open label study to assess the safety and effectiveness of microneedling with cbd and hempseed oil for the treatment of moderate to severe acne in adults 22-years of age or older.the objective of this exploratory study is to evaluate the safety and efficacy of healmd's cbd with hempseed oil to reduce the appearance of moderate to severe facial acne.


Eligibility criteria:
inclusion criteria: * male or non-pregnant, non-lactating female, 22 years of age or older. females of childbearing potential must agree to the use of a reliable method of contraception throughout the study. * have a global acne severity scale score of 3 (moderate), 4 (severe), or 5 (very severe). * have no plans to begin a new skincare routine or medical treatment program (accutane) through the course of the study. * willing to abstain from any aesthetic or surgical procedure in the treatment area for the duration of the study. exclusion criteria: * significant history or current evidence of any uncontrolled chronic or serious disease or medical condition that would, in the judgment of the investigator, would put the subject at undue risk or compromise the study assessments. * employees of the investigator or research center or their immediate family members. * inability to understand the requirements of the study and the relative information and are unable or not willing to comply with the study protocol. * the use of accutane (isotretinoin) within 6-months. * the use of topical or oral therapies that include benzoyl peroxide, azelaic acid, salicylic acid, and hydroquinone 30 days prior to study entry. * exposure to any other investigational drug/device within 30 days prior to study entry. * sunburned at time of anticipated treatment. subject must also be willing to avoid significant sun exposure throughout participation * recent facial plastic surgery, aesthetic treatment, or dermatological treatment at treatment sites that would interfere with ability to receive microneedling. * facial hair that would interfere with the visualization of treatment sites. * subject with abnormal vision assessments. * subject is known to be noncompliant or is unlikely to comply with the requirements of the study protocol (e.g. due to alcoholism, drug dependency, mental incapacity) in the opinion of the investigator.
mirabegron and urinary urgency incontinence

Conditions: Overactive Bladder

Summary: this study is for women diagnosed with urinary urgency incontinence (uui) or overactive bladder (oab). some patients continue to have symptoms even while taking medication for oab. the purpose of this study is to estimate the number of women who respond to a medication called mirabegron and estimate change in symptom severity over 12 weeks of therapy. a secondary goal is to correlate the female urinary microbiome (fum) with response to treatment and change in symptom severity over 12 weeks of therapy.

mirabegron is an fda-approved medication for urgency incontinence. evaluation of mirabegron's influence on clinical symptoms may need to take into account the effect of the female urinary microbiome (fum) on a patient's response to treatment. compared to asymptomatic patients, several bacterial species are more common in patients with overactive bladder. currently, physicians have limited ability to personalize a patient's urinary urgency incontinence treatment and, consequently, the prescribed medication may provide minimal symptom relief. since the fum can be assessed prior to treatment, this study proposes to determine if baseline fum assessment can provide insight into future symptom relief with mirabegron treatment.

Eligibility criteria:
inclusion criteria: * bothersome idiopathic (non-neurologic) urgency urinary incontinence (uui) who recall ≥ 5 urgency predominant urinary incontinence episodes in the prior week (urgency urinary incontinence or mixed urinary incontinence-urgency predominant) * no contraindications to taking mirabegron * patients on current oab therapy will undergo a two-week drug washout period prior to baseline assessment exclusion criteria: * neurologic disease known to affect the lower urinary tract * systemic immunologic deficiency * current urinary tract infection (uti) (based on dipstick assessment) or recurrent culture-proven utis * history or current pelvic malignancy or radiation * untreated symptomatic pelvic organ prolapse (pop) \> pop-q stage ii * a contraindication to receiving mirabegron * women of childbearing potential who are pregnant or nursing or intend to become pregnant during the study, or who are not practicing a reliable method of contraception * must not have taken any antibiotics in the 4 weeks prior to enrollment

Keywords: urinary urgency incontinence mirabegron myrbetriq betmiga
acute and chronic responses to blood pressure after exercise

Conditions: Arterial Hypertension

Summary: the study will evaluate the variability of blood pressure in postmenopausal and hypertensive women after only one session and after training of ten weeks of combined physical exercises (aerobic and resisted).

before starting the training program, all the volunteers will sign the free and informed consent form (tcle) and must present a medical certificate releasing the participation. in addition, the volunteers will respond to an anamnesis questionnaire and will undergo an anthropometric evaluation before the experimental sessions. the physical exercise program will be held three times a week for 10 weeks, containing aerobic exercise (exercise treadmill) and resistance exercises (bodybuilding). initially, a familiarization of the ergometers used will be performed, followed by a session to evaluate the intensity of resistance exercise through a maximal repetition test (1rm), and a session to evaluate aerobic fitness through an incremental treadmill test. before starting the training, volunteers will perform a single exercise session, following the same exercise protocol. all the volunteers will be submitted to the evaluation of the blood pressure during 24 hours through the measurement of ambulatory blood pressure (abpm) in three moments: * pr: pre-training rest - the volunteers will arrive at the laboratory, will be in rest for 15 minutes and after that they will place the abpm, without having done any exercise. * pe: post exercise - upon arriving at the laboratory, the volunteers will be submitted to a single combined exercise session, will have a maximum interval of 20 minutes for the bath and will place the map device. * cr: rest after chronic training - after the end of the 10 weeks of training, the volunteers will be submitted to abpm, again at rest, with a maximum interval of 72 hours, between the end of the training and the placement of the device.

Eligibility criteria:
inclusion criteria: * women aged between 50 and 70 years; * be in the postmenopausal phase; * be able to practice physical exercise on treadmill and resistance exercises (bodybuilding). * present stage 1 hypertension, according to the guidelines of the brazilian society of hypertension * make use of anti-hypertensive medication, except beta-blockers * participants should be evaluated with a cardiologist beforehand and present a certificate attesting that they are able to perform physical activities. * do not present physical problems or cardiovascular complications that prevent the performance of physical exercises. exclusion criteria: * make use of beta-blockers * present history of stroke or acute myocardial infarction; * smoking; * present diagnosis of diabetes mellitus. * present renal pathologies * use hormone replacement therapies

Keywords: blood pressure variability combined physical exercise hypertension
is detoxification needed in medication-overuse headache?

Conditions: Medication Overuse Headache

Summary: medication-overuse headache (moh) is a disabling condition, yet treatable. according to european guidelines and based on evidence, multidisciplinary detoxification is the first choice of treatment for moh. however, consensus about the details in such detoxification programs is lacking. contrary, other headache specialists believe more in treating chronic headache with medication overuse with single-therapy of prophylaxis and no withdrawal of acute medication, based on randomized controlled double-blinded placebo trial with prophylaxes. only a single rct has compared single-therapy with prophylaxis to detoxification. however there was no significant difference. aim: 1. to compare three different treatment protocols in order to improve the therapy of moh. 2. to test several baseline variables for being potential predictors for good treatment outcome. 3. to examine the role of epigenetics in moh.


Eligibility criteria:
patients with medication-overuse headache: inclusion criteria: * confirmed moh diagnosis according to the ichd-iii beta (1). * eligible for outpatient treatment based on type of medication overuse (without massive pure opioids and barbiturates overuse), and personal resources and motivation. * capable of completing headache diary/calendar. * age ≥ 18 years old and capable of providing informed consent. * medication-overuse headache based on initial tension-type headache (tth) or migraine. * signed informed consent. exclusion criteria: * severe physical illness or psychiatric disorders. * addiction to alcohol or other drugs. * current treatment with headache prophylaxis. patients can be included minimum 5 weeks after stop of prophylaxis. * pregnancy, breastfeeding or planned pregnancy within the next 12 months. * inability to provide reliable information about medical history. criteria for control group 1 - episodic migraineurs: * episodic migraine, with/without concomitant tension-type headache, according to the ichd-iii beta. * headache days / month ≤ 6 at time of inclusion. * days with analgesics / month ≤ 6 at time of inclusion. * prophylactics are allowed. * age ≥ 18 years old. * ability to fill out headache calendar. * no previous medication overuse. * no significant co-morbid pain, physical or psychiatric disorders. * no addiction to alcohol or drug-abuse. * no pregnancy, breastfeeding or planned pregnancy within the next 12 months. criteria for control group 2 - healthy volunteers: •≥ 2 days with headache in the past month at time of inclusion. * days with analgesics / month ≤ 6 at time of inclusion. * age ≥ 18 years old. * no significant co-morbid pain, physical or psychiatric disorders. * no addiction to alcohol or drug-abuse. * no pregnancy, breastfeeding or planned pregnancy within the next 12 months.
condor study of osteonecrosis of the jaws (tmj)

Conditions: Osteonecrosis of the Jaw

Summary: the purpose of this study was to examine risk factors for osteonecrosis of the jaw (onj), including the possible association with bisphosphonates (bps). this study used the research infrastructure from the three nidcr-funded dental practice-based research networks (dpbrn, pearl, precedent). de-identified data from the dpbrn were merged with comparable de-identified data from pearl and precedent to form a single trans-pbrn data set used for analysis.

the aims of this study were to (1) test the hypothesis that (bp) treatment is a risk factor for (onj); (2) to test the hypothesis that dental diseases (particularly periodontal disease), and invasive dental procedures such as dental extractions are true risk factors for (onj).

Eligibility criteria:
inclusion criteria: * participants directly involved in this study were patients of dentists from the dental practice based research networks (dpbrn, pearl, precedent). exclusion criteria: * participants with a history of sickle cell anemia * participants with a history of external severe trauma to the jaws

Keywords: onj
access 2: ai for pediatric diabetic eye exams study 2

Conditions: Type 1 Diabetes; Type 2 Diabetes; Cystic Fibrosis-related Diabetes

Summary: the purpose of this study is to determine if use of a nonmydriatic fundus camera using autonomous artificial intelligence software at the point of care increases the proportion of underserved youth with diabetes screened for diabetic retinopathy.

this study will recruit 500 individuals ages 8-21 with type 1 and type 2 diabetes. participants will undergo a point-of-care diabetic eye exam using autonomous ai software on a non-mydriatic fundus camera. participants will receive the diabetic eye exam results immediately from the autonomous ai system, and if abnormal will be referred to an eye care provider for a dilated eye exam. the autonomous ai interpretation will also be compared to consensus grading of retinal specialists to determine if there is agreement.

Eligibility criteria:
inclusion criteria: meets american diabetes association (ada) criteria for diabetic retinopathy screening: * diagnosis of type 1 diabetes for ≥3 years, and age 11 or in puberty * diagnosis of type 2 diabetes exclusion criteria: * known diabetic eye exam in the last 12 months

Keywords: diabetic retinopathy
lv endocardial cardiac resynchronisation therapy

Conditions: Heart Failure

Summary: cardiac resynchronisation therapy (crt) is an established treatment for severe systolic heart failure with well documented benefits in symptom improvement and reduction of morbidity and mortality. however, upto 30% of patients do not respond to treatment despite fulfilling the recommended indications. lack of clinical response may be the result of imperfect left ventricular lead placement in the veins around the heart with conventional techniques. optimum lead placement may constrained by coronary venous anatomy and may overlie scarred heart muscle or may not be at the site of latest electrical depolarisation. in a further 10% of patients, conventional left ventricular lead placement is not possible for other technical reasons. left ventricular endocardial lead placement may overcome the limitations and allow placement to be guided by echocardiography, electrical mapping and the pattern of heart muscle scarring. we aim to investigate if targeted left ventricular endocardial lead placement improves exercise capacity, heart failure symptoms, heart function and size, heart pumping efficiency and biochemical markers of heart strain. each parameter will be assessed independently and as part of a composite cardiac performance score. patients with heart failure will be enrolled who require an endocardial left ventricular lead on clinical grounds as either conventional left ventricular lead implantation has technically failed or they have clinically non-responded to crt.


Eligibility criteria:
inclusion criteria: * age greater than 18 years * nyha class ii-iv * lvef ≤35% * qrs ≥120 milliseconds * optimal tolerated medical therapy * either unable to position an lv lead via the standard coronary sinus on crt implantation * or recipient of a crt-p or crt-d system for greater than 6 months for standard indications and limited improvement or worsened clinical status despite device optimisation * informed consent exclusion criteria: * life-expectancy less than 1 year due to concomitant, non-cardiovascular disorders * previous atrial septal defect device closure. * chronic renal dialysis and end stage liver disease * history of stroke, myocardial infarction, unstable angina, coronary artery bypass grafting and coronary stenting within the last 3 months * presence of correctable valvular disease (aortic/mitral) * mitral valve prosthesis. * contra indication to vitamin k antagonist * unresolved intra-cardiac thrombus * pregnancy

Keywords: heart failure cardiac resynchronisation therapy transseptal left ventricular endocardial lead
protocollo n 2014 - benign prostatic hyperplasia

Conditions: Benign Prostatic Hyperplasia

Summary: prospective observational study on the quality of life of patients with bph under medical therapy and/or undergoing surgery.

prospective observational study on the quality of life of patients with bph under medical therapy and/or undergoing surgery. data relating to the clinical conditions (state of the disease, psychological and related to the quality of life) of patients suffering from bph under medical therapy and/or undergoing surgery will be collected within a specially designed database which will allow us to easily and secure extraction of data used for statistical analyzes in clinical research.

Eligibility criteria:
inclusion criteria: * subjects suffering from benign prostatic hyperplasia undergoing medical therapy and/or undergoing surgery * subjects \>= 18 years old * signature of informed consent exclusion criteria: * subjects \< 18 years * presence of mental or physical disability that may prevent the patient from answering the questionnaires.

Keywords: benign prostatic hyperplasia; urology